The global HLA typing market is expected to reach USD 1.73 billion by 2030, according to a new report by Grand View Research, Inc. The increasing stem cell transplantation coupled with expanding the use of HLA typing in other applications is expected to support the growth of the HLA matching market. From 2016 to 2020, around 111,984 hematopoietic cell transplantations were performed in the U.S. Out of those, 89% of cell sources were peripheral blood, 9% were from bone marrow and 2% were from cord blood. Similarly, there are over 219 centers in the region for performing hematopoietic cell transplantations.
HLA matching is expected to be a valuable source of information for various basic and translational research studies. Since some HLA alleles can impact the severity and susceptibility of infectious diseases, while other HLA alleles are related to the diverse predispositions of genetics to diseases such as autoimmune conditions and cancer. Gaining insights into which haplotypes can have a higher probability of critical disease or poor prognosis can be specifically useful in translational applications for developing therapeutics. Hence, HLA typing usage in research applications is expected to have a considerable contribution to the overall human leukocyte antigen matching market estimates.
The COVID-19 pandemic adversely impacted the HLA matching market. Although there was a handful of researchers with the concept of integrating HLA typing with COVID-19 testing. For instance, in August 2021, the scientific evidence from research published in the European Journal of Medical Research suggested including HLA tying in clinical trials and combining it with the COVID-19 test to increase the speed of identifying a predictor in the population.
The growing strategic initiatives by the companies are anticipated to boost human leukocyte antigen matching market growth. For instance, in March 2022, Immucor, Inc. announced to launch a HLA typing software as a supporting product for its HLA typing assay. The software is expected to ease and quicker the NGS analysis process with a cost-saving option for the users.
On the other hand, the increasing number of recipients removed from the waiting list for organ transplantation is likely to affect the usage of HLA typing. The reasons for the removal from the list are deterioration in the patient's condition, patient’s death, or recovery from the disease. For instance, from January 2021 to December 2021, 6 patients from Barnes-Jewish Hospital died due to the shortage of organs, while 11 patients’ conditions deteriorated.
Request a free sample copy or view report summary: HLA Typing Market Report
By product, the reagents & consumables segment is projected to establish the fastest growth rate over the forecast period. Since increasing product development by the existing players to expand the usage of HLA typing in various fields of research, such as immunotherapies.
By application, the diagnosis segment is anticipated to have the fastest growth rate with a larger share in 2022. Owing to the increase in organ transplantations and showcasing evidence of being an important source of information for infectious diseases, hence, propelling the HLA matching market growth.
By technique, the sequenced-based molecular assay segment is anticipated to have the fastest-growing CAGR between 2023 to 2030. Since, it has the ability to generate clear, phase-resolved HLA typing with a single assay.
By end-user, the hospitals and transplant centers segment is projected to have a majority of the human leukocyte antigen matching market share in 2022. This is attributed to the presence of well-equipped facilities for research in developed countries.
North America has strengthened its regional position in the market with 46.94% of the overall market share. This is attributed to the presence of transplant centers and clinics, along with the existence of key players in the region.
A few of the key market players include Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Omixon Inc., GenDx, Illumina Inc., and others.
Grand View Research has segmented the global HLA typing market based on product, application, technique, end user, and region:
HLA Typing Product Scope Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Reagents & Consumables
Software & Services
HLA Typing Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
Diagnosis
Research
HLA Typing Technique Scope Outlook (Revenue, USD Million, 2018 - 2030)
Molecular Assay
Sequenced-based Molecular Assay
Non-Molecular Assay
HLA Typing End user Scope Outlook (Revenue, USD Million, 2018 - 2030)
Commercial Service Providers
Hospitals & Transplant Centers
Research Labs & Academic Institutes
HLA Typing Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of HLA Typing Market
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Qiagen N.V.
Omixon Inc.
GenDx
Illumina Inc.
TBG Diagnostics Limited
Dickinson and Company
Takara Bio Inc.
F. Hoffman-La Roche Limited
Pacific Biosciences
"The quality of research they have done for us has been excellent..."